Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Anti-CMV (UL97 inhibitor)

Maribavir

Brand names: Livtencity

Maribavir is an antiviral agent used to treat cytomegalovirus (CMV) infection and disease that is refractory, with or without resistance, to prior anti-CMV therapy, particularly after transplantation.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits the CMV UL97 protein kinase, interfering with viral DNA replication, encapsidation and nuclear egress of viral particles.

Prescribing in practice

  • Because it inhibits UL97, it antagonises ganciclovir and valganciclovir, which depend on UL97 for activation, so co-administration with these agents should be avoided.
  • Resistance can emerge during treatment, so persistent or rising CMV viral load should prompt reassessment.
  • It interacts with several drugs as a CYP3A substrate and a P-glycoprotein inhibitor, so co-medication should be reviewed against current prescribing references.

Monitoring

Monitor CMV viral load to assess response and detect possible resistance during treatment.

Counselling the patient

  • This medicine treats a CMV infection that did not respond to earlier treatment.
  • Taste disturbance is a common side effect and usually settles.
  • Attend blood tests to check that the virus is responding.

Evidence & guidelines

A randomised controlled trial demonstrated superiority over investigator-assigned anti-CMV therapy for clearance of refractory or resistant CMV infection.

Reference: NICE TA860; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways